Fig. 7

In vivo targeting potential of PLT@Ag-MOF-Vanc. a In vivo fluorescence images of MRSA pneumonia mice at 6, 24, and 48 h upon intravenous treatment with Cy5-labeled Ag-MOF-Vanc and Cy5-labeled PLT@Ag-MOF-Vanc. b Ex vivo bioluminescence images of visceral organs at 48 h after treatment with Cy5-labeled Ag-MOF-Vanc and Cy5-labeled PLT@Ag-MOF-Vanc. c Semiquantitative assessment of fluorescence signals of visceral organs. Control = mouse MRSA pneumonia model without any injection. Data are mean ± SD (n = 3). *p < 0.05, ***p < 0.001